![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, July 12, 2022 9:04:41 PM
Don4, any “hopium” here?
It'll be interesting what the data says. The 78% of the LIVE-AIR trial that had a CRP<150mg/L had great data but the 25% of the the LIVE-AIR that had a CRP<41mg/L had 733% efficacy. Hopefully, the ACTIV data reconfirms this. So maybe there is still hope for moderate patients or very early severe patients. Obviously, that would require another trial. We'll have to see the data. CAR-T is still promising. My guess is that there will be a Big Pharma buyout which will at least help investors recoup some of their losses.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM